| Schedule of Segment Information |
The following table provides information about our single segment:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | | Operating Expenses: | | | | | | | | | | Significant components of research and development (R&D) expenses: | | | | | | | | | | Clinical trial expenses | | $ | 1,056 | | | $ | 422 | | | $ | 1,803 | | | $ | 792 | | | Manufacturing and related process development expenses | | 413 | | | 425 | | | 920 | | | 839 | | | Personnel-related expenses | | 2,699 | | | 1,045 | | | 5,970 | | | 3,026 | | | Significant components of general and administrative (G&A) expenses: | | | | | | | | | | Public company-related expenses | | 3,368 | | | 1,580 | | | 6,384 | | | 2,780 | | | Personnel-related expenses | | 1,371 | | | 888 | | | 2,601 | | | 1,625 | | | Intellectual property expenses | | 149 | | | 85 | | | 451 | | | 192 | | | All other R&D and G&A expenses | | 323 | | | 206 | | | 531 | | | 418 | | | Total operating expenses | | 9,379 | | | 4,651 | | | 18,660 | | | 9,672 | | | Loss from operations | | (9,379) | | | (4,651) | | | (18,660) | | | (9,672) | | | Total other income (expense), net | | 38 | | | (565) | | | 76 | | | (255) | | | Income tax expense | | (101) | | | (61) | | | (101) | | | (61) | | | Net loss | | $ | (9,442) | | | $ | (5,277) | | | $ | (18,685) | | | $ | (9,988) | |
|